Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

NCT06216301 is registered in ClinicalTrials.gov with NovoCure GmbH as lead sponsor.

NCT NCT06216301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06216301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Lead sponsor
NovoCure GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
July 31, 2024
Completion date
October 31, 2028
Enrollment
734 (estimated)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer